Summit Therapeutics valuation
$10.67Change from previous close: −9.73%Absolute change: −$1.15
Valuation
The average price target of 13 analysts is $29.54.
Data as of November 15, 2026
Summit Therapeutics compared with similar companies
Summit Therapeutics's Price/book: 20.0, +52% against the median of a group of 10 similar companies (13.2).
| Metric | Summit Therapeutics | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| Price/book | 20.0 | 13.2 | 6.20 – 17.5 | High |
| Gross margin | 0.0% | 91.0% | 59.7% – 93.1% | Low |
| Operating margin | 0.0% | 16.3% | -5.3% – 29.2% | Middle |
| Net margin | 0.0% | 4.4% | -5.7% – 19.4% | Middle |
| ROE | -220.0% | 8.2% | -9.7% – 38.5% | Low |
| Debt/equity | 0.04 | 0.13 | 0.06 – 0.62 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $11.32B
- Enterprise value
- $10.71B
- P/E (trailing 12 months)
- -12.2
- Forward P/E
- -13.7
- EV/EBITDA
- -12.5
Profitability and growth
- ROA
- -112.0%
- ROIC
- -136.6%
Financial health
- Total cash
- $629.79M
- Total debt
- $19.98M
- Current ratio
- 5.99
- Quick ratio
- 5.71
- Piotroski F-Score
- 2.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $29.54
- Median price target
- $32.65
- High price target
- $42.23
- Low price target
- $11.73
- Analysts with a price target
- 13
- Consensus
- Buy
- Forward EPS
- -$1.03
- EPS estimate, current year
- -$0.79
Shares and trading
- Beta
- -1.52
- Average volume
- 6.18M
- Shares outstanding
- 799.76M
- Float
- 154.3M
- Institutional ownership
- 17.1%
- Insider ownership
- 81.0%
- Short interest (% of float)
- 26.7%
- Short ratio (days)
- 7.56
